Sector News

Bayer, Sensyne to form new AI ‘LifeHub’

October 10, 2019
Life sciences

Sensyne has announced a new partnership – its second this week – with Bayer, in order to accelerate the development of new treatments using clinical artificial intelligence.

The company revealed that it will work in partnership with the German pharma giant on novel projects at the LifeHub UK, including its inaugural project – the development of AI-enabled radiology to enhance patient outcomes.

LifeHub UK, which launches today, forms part of a global network of Bayer innovation hubs, designed to accelerate and optimise disease detection and data-driven drug discovery by enabling Artificial Intelligence (AI)-enabled imaging solutions.

The companies have announced that the first LifeHub UK project will focus on the development of AI-enabled radiology solutions using Sensyne Health’s proprietary clinical AI technology platform to identify digital solutions for automated image evaluation.

The project will analyse research from three million anonymised, ethically sourced NHS patient records and imaging data provided through Sensyne Health’s partnerships with NHS trusts, developing digital solutions to help radiologists improve the quality of the diagnosis and increase efficiency for patients receiving the right treatment in a timely manner.

Kemal Malik, Bayer board member for innovation, said that the company is “delighted to launch LifeHub UK,” and that it firmly believes “artificial intelligence has transformative potential for healthcare, leading to enhancements in prediction, prevention and personalised treatments.

“LifeHub UK’s roadmap is a perfect fit to Bayer’s Open Innovation strategy, which is designed to leverage places, programmes and partnerships – such as strategic alliances and joint ventures – in the life sciences fields of pharmaceuticals and agriculture.”

Earlier this week Sensyne announced a formal research agreement with the UK Medicines and Healthcare Products Regulatory Agency (MHRA), to contribute to the development of methods to validate software algorithms used in digital health.

The company is also already part of a partnership with the University of Oxford’s Big Data Institute (BDI), using data science and clinical artificial intelligence (clinical AI) for the patient-centred management and treatment of chronic disease.

By Anna Smith

Source: Pharma Times

Related News

August 13, 2020

Novozymes posts resilient performance despite COVID-19, reinstates 2020 outlook

Life sciences

Novozymes says its net profits for the second quarter of 2020 dropped 28% year on year (YOY), to 646 million Danish krone ($102 million) on 3% YOY lower sales, to […]

August 11, 2020

UCB’s Cimzia bags EU label extension

Life sciences

The European Medicines Agency (EMA) has approved a label extension for UCB’s Cimzia (certolizumab pegol) for adult patients with axial spondyloarthritis (axSpA) at a reduced maintenance dose. This means that […]

August 11, 2020

Pfizer inks manufacturing deal with Gilead for COVID-19 med remdesivir

Life sciences

Pfizer has inked a multi-year agreement with Gilead Sciences to manufacture and supply the investigational antiviral drug remdesivir for the treatment of COVID-19. Under the terms of the agreement, Pfizer […]